Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy-Reference-Cited by-同舟云学术

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy

Published:2024-09-06 Issue: Volume: Page:
ISSN:0341-2040
Container-title:Lung
language:en
Short-container-title:Lung

Author:

Söllner Julia F.,Bentink Stefan,Hesslinger Christian,Leonard Thomas B.,Neely Megan L.^ORCID,Patel Nina M.,Schlange Thomas^ORCID,Todd Jamie L.^ORCID,Vinisko Richard,Salisbury Margaret L.^ORCID,

Funder

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00408-024-00742-x.pdf

Reference17 articles.

1. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18–e47

2. Snyder L, Neely ML, Hellkamp AS, O’Brien E, de Andrade J, Conoscenti CS et al (2019) Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res 20:105

3. Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M et al (2020) Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J 56:1902279

4. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA (2009) Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 4:e5134

5. Huang Y, Oldham JM, Ma SF, Unterman A, Liao SY, Barros AJ et al (2021) Blood transcriptomics predicts progression of pulmonary fibrosis and associated natural killer cells. Am J Respir Crit Care Med 204:197–208